|
|
Article: Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint.
- Article from:
- Blood Weekly
- Article date:
- March 26, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) announced that a Phase III study of Rituxan[R] (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks. The primary endpoint evaluated improvements in kidney response as measured by standard laboratory tests used to assess kidney health. A preliminary analysis of the safety data did not reveal any new or unexpected safety signals in patients receiving Rituxan (see also Genentech, Inc.).
Lupus nephritis is an inflammation of the kidney and a complication of systemic lupus ...